Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jonathan Adam Feldschuh is Chief Scientific Officer at Daxor. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 25, 2026, each linked to the official Form 4.
Chief Scientific Officer
Disclosures on record
1
Companies involved
1
DaxorDXR
Jun 23, 202625Kdisclosed Jun 25
DetailsOfficial recordAs of the latest filing on , Jonathan Adam Feldschuh reported holding 78,908 shares of Daxor (DXR), worth about $659K at the last close of $8 (Nov 16, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Daxor DXR | 78,908 | 79K direct | $8 | $659K | Jun 23, 2026 |
Is this Jonathan Adam Feldschuh’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jun 23, 2026, Jonathan Adam Feldschuh reported holding 78,908 shares of Daxor (DXR). At the last close of $8 on Nov 16, 2026, that is about $659K. This is the stake disclosed in filings, not a net worth.
Jonathan Adam Feldschuh has no open-market purchase on record since 2018. Sales in 1 of the 9 years since 2018.
In SEC filings since 2018: no open-market purchase is on record; the latest open-market sale is from 2018.
Daxor (DXR), from 2018 to 2018: 0 purchases and 1 sale.
Jonathan Adam Feldschuh has no open-market purchase on record since 2018. Sales in 1 of the 9 years since 2018.
Jonathan Adam Feldschuh reported 0 open-market purchases and 1 sale since 2018; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2018 | — | $358K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Jonathan Adam Feldschuh reported 0 open-market purchases and 1 sale here, 2018.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.